NEW YORK (GenomeWeb) ­­– Vermillion reported after the close of the market on Thursday an 89 percent jump in its first quarter revenues

For the three months ended Sept, 30, the Austin, Texas-based cancer diagnostics firm said that total revenues rose to $623,000 from $330,000 in the year-ago quarter.

Product revenues were $581,000, up from $330,000 in Q3 2015. Service revenues from the company's Aspira IVD business was $42,000. Vermillion had no service revenues in Q3 2015 as Aspira IVD was not yet operating.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.